instruction:
In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.
question:
SECTION 1. SHORT TITLE.

This Act may be cited as the ''Tuition Assistance for Families
Act''.

SEC. 2. EXPANSION OF TUITION TAX DEDUCTION.

(a) In General.--Subparagraphs (A) and (B) of section 222(b)(2) of
the Internal Revenue Code of 1986 (relating to dollar limitation) are
amended to read as follows:
''(A) In general.--The applicable dollar limit
shall be equal to--
''(i) in the case of a taxpayer whose
adjusted gross income for the taxable year does
not exceed $65,000 ($130,000 in the case of a
joint return), $12,000,
''(ii) with respect to any taxable year
beginning in 2004 or 2005, in the case of a
taxpayer not described in clause (i) whose
adjusted gross income for the taxable year does
not exceed $80,000 ($160,000 in the case of a
joint return), $2,000, and
''(iii) in the case of any other taxpayer,
zero.
''(B) Inflation adjustment.--
''(i) In general.--In the case of any
taxable year beginning after 2003, each dollar
amount referred to in subparagraph (A)(i) shall
be increased by an amount equal to--
''(I) such dollar amount,
multiplied by
''(II) the cost-of-living
adjustment determined under section
(1)(f)(3) for the calendar year in
which the taxable year begins, by
substituting '2002' for '1992'.
''(ii) Rounding.--If any amount as adjusted
under clause (i) is not a multiple of $100,
such amount shall be rounded to the next lowest
multiple of $100.''.
(b) Permanent Deduction.--Section 222 of the Internal Revenue Code
of 1986 (relating to qualified tuition and related expenses) is amended
by striking subsection (e).
(c) Effective Date.--The amendments made by this section shall
apply to payments made in taxable years beginning after December 31,
2002.

SEC. 3. EXPANSION OF LIFETIME LEARNING CREDIT.

(a) In General.--Section 25A(c)(1) of the Internal Revenue Code of
1986 (relating to per taxpayer credit) is amended--
(1) by striking ''20 percent'' and inserting ''25
percent'', and
(2) by striking ''$10,000 ($5,000 in the case of taxable
years beginning before January 1, 2003)'' and inserting
''$12,000''.
(b) Inflation Adjustment.--Section 25A(h) of the Internal Revenue
Code of 1986 (relating to inflation adjustments) is amended by adding
at the end the following new paragraph:
''(3) Dollar limitation on amount of lifetime learning
credit.--
''(A) In general.--In the case of any taxable year
beginning after 2003, the dollar amount referred to in
subsection (c)(1) shall be increased by an amount equal
to--
''(i) such dollar amount, multiplied by
''(ii) the cost-of-living adjustment
determined under section (1)(f)(3) for the
calendar year in which the taxable year begins,
by substituting '2002' for '1992'.
''(B) Rounding.--If any amount as adjusted under
subparagraph (A) is not a multiple of $100, such amount
shall be rounded to the next lowest multiple of
$100.''.
(c) Effective Date.--The amendments made by this section shall
apply to payments made in taxable years beginning after December 31,
2002.

SEC. 4. INCREASE IN INCOME LIMITS FOR HOPE AND LIFETIME LEARNING
CREDITS.

(a) In General.--Section 25A(d)(2)(A)(ii) of the Internal Revenue
Code of 1986 (relating to limitation based on modified adjusted gross
income) is amended by striking ''$40,000 ($80,000'' and inserting
''$55,000 ($110,000''.
(b) Conforming Amendments.--Section 25A(h)(2)(A) of the Internal
Revenue Code of 1986 is amended--
(1) by striking ''2001'' in the matter preceding clause (i)
and inserting ''2003'',
(2) by striking ''the $40,000 and $80,000 amounts'' in such
matter and inserting ''the $55,000 and $110,000 amounts'', and
(3) by striking ''2000'' in clause (ii) and inserting
''2002''.
(c) Effective Date.--The amendments made by this section shall
apply to payments made in taxable years beginning after December 31,
2002.

SEC. 5. MAXIMUM PELL GRANT AWARDS.

The Department of Education Appropriations Act, 2002 (Public Law
107-116) is amended under the heading ''Student Financial Assistance''
by striking ''$4,000'' and inserting ''$4,500''.

SEC. 6. ACADEMIC ACHIEVEMENT SCHOLARSHIPS.

(a) Scholarships.--The Secretary of Education is authorized to
award a scholarship for academic year 2003-2004 and succeeding academic
years to each student in a State who graduated in the top 5 percent of
such student's graduating class from secondary school in academic year
2002-2003 or a succeeding academic year to enable such student to pay
the cost of attendance at an institution of higher education.
(b) Amount.--Each scholarship awarded under this section shall be
in the amount of $1,000.
(c) Use.--Each student awarded a scholarship under this section
shall use the funds to pay the cost of attendance at an institution of
higher education.
(d) Construction of Needs Provision.--
(1) In general.--Except as provided in paragraph (2),
nothing in this section, or any other Act, shall be construed
to permit the receipt of a scholarship under this section to be
counted for any needs test in connection with the awarding of
any grant or the making of any loan under the Higher Education
Act of 1965 (20 U.S.C. 1001 et seq.) or any other provision of
Federal law relating to educational assistance.
(2) Exception.--In determining the need of a student for
Federal financial assistance, an institution of higher
education may take into consideration the amount of scholarship
assistance received under this section if the total amount of
scholarship assistance received under this section plus the
amount of other financial assistance available to a student
exceeds the student's cost of attendance at the institution.
(e) Regulations.--The Secretary of Education shall promulgate
regulations regarding how scholarships awarded under this section will
be allocated to both public and private school students.
(f) Definitions.--In this section:
(1) Cost of attendance.--The term 'cost of attendance' has
the meaning given the term in section 472 of the Higher
Education Act of 1965 (20 U.S.C. 1087ll).
(2) Institution of higher education.--The term 'institution
of higher education' has the meaning given the term in section
101 of the Higher Education Act of 1965 (20 U.S.C. 1001).
answer:
Tuition Assistance for Families Act - Amends the Internal Revenue Code to expand the tax deduction for qualified higher education tuition and related expenses. Sets such deduction at: (1) $12,000 for those with incomes up to $65,000 single or $130,000 joint; and (2) $2,000 for those whose incomes are above that level, but not more than $80,000 single or $160,000 joint. Provides inflation adjustment. Makes such tuition deduction permanent.Increases the amount of the Lifetime Learning tax credit percentage from 20 to 25 percent. Increases the amount of education expenses subject to such credit from $10,000 to $12,000 (thus making the maximum allowable credit $3,000, rather than the current $2,000). Provides inflation adjustment.Raises annual income limits for the Hope and Lifetime Learning tax credits to $55,000 single and $110,000 joint.Amends the Department of Education Appropriations Act, 2002 (Public Law 107-116) to increase the maximum Pell Grant award from $4,000 to $4,500.Establishes an academic achievement scholarship program. Authorizes the Secretary of Education to award a $1,000 college scholarship to each student in a State who graduates in the top five percent of his or her secondary school's graduating class.

question:
SECTION 1. SHORT TITLE.

This Act may be cited as the ''Tiffany Joslyn Juvenile
Accountability Block Grant Program Reauthorization Act of 2016''.

SEC. 2. REAUTHORIZATION OF JUVENILE ACCOUNTABILITY BLOCK GRANT PROGRAM.

Part R of title I of the Omnibus Crime Control and Safe Streets Act
of 1968 (42 U.S.C. 3796ee et seq.) is amended--
(1) in section 1801(b)--
(A) in paragraph (1), by striking ''graduated
sanctions'' and inserting ''graduated sanctions and
incentives''; and
(B) in paragraph (3), by striking ''hiring juvenile
court judges, probation officers, and court-appointed
defenders and special advocates, and'';
(C) by striking paragraphs (4) and (7), and
redesignating paragraphs (5) through (17) as paragraphs
(4) through (15), respectively; and
(D) in paragraph (11), as so redesignated, by
striking ''research-based bullying, cyberbullying, and
gang prevention programs'' and inserting
''interventions such as researched-based anti-bullying,
anti-cyberbullying, and gang prevention programs, as
well as mental health services and trauma-informed
practices'';
(2) in section 1802--
(A) in subsection (d)(3), by inserting after
''individualized sanctions'' the following: '',
incentives,'';
(B) in subsection (e)(1)(B), by striking
''graduated sanctions'' and inserting ''graduated
sanctions and incentives''; and
(C) in subsection (f)--
(i) in paragraph (2)--
(I) by inserting after ''A sanction
may include'' the following: ''a range
of court-approved interventions, such
as''; and
(II) by inserting after ''a fine,''
the following: ''a restorative justice
program,''; and
(ii) by inserting after paragraph (2) the
following:
''(3) Incentives.--The term 'incentives' means
individualized, goal-oriented, and graduated responses to a
juvenile offender's compliance with court orders and case
disposition terms designed to reinforce or modify the skills
and behaviors of the juvenile offender. An incentive may
include a certificate of achievement, a letter of
recommendation, a family or program activity, a meeting or
special outing with a community leader, a reduction in
community service hours, a reduced curfew or home-restriction,
a decrease in required court appearances, or a decrease in the
term of court-ordered supervision.'';
(3) in section 1810(a), by striking ''$350,000,000 for each
of fiscal years 2006 through 2009'' and inserting ''$25,000,000
for each of fiscal years 2018 through 2022''; and
(4) by adding at the end the following:

''SEC. 1811. GRANT ACCOUNTABILITY.

''(a) Definition of Applicable Committees.--In this section, the
term 'applicable committees' means--
''(1) the Committee on the Judiciary of the Senate; and
''(2) the Committee on the Judiciary of the House of
Representatives.
''(b) Accountability.--All grants awarded by the Attorney General
under this part shall be subject to the following accountability
provisions:
''(1) Audit requirement.--
''(A) Definition.--In this paragraph, the term
'unresolved audit finding' means a finding in the final
audit report of the Inspector General of the Department
of Justice that the audited grantee has utilized grant
funds for an unauthorized expenditure or otherwise
unallowable cost that is not closed or resolved within
12 months after the date on which the final audit
report is issued.
''(B) Audit.--Beginning in the first fiscal year
beginning after the date of enactment of this section,
and in each fiscal year thereafter, the Inspector
General of the Department of Justice shall conduct
audits of recipients of grants awarded by the Attorney
General under this part to prevent waste, fraud, and
abuse of funds by grantees. The Inspector General shall
determine the appropriate number of grantees to be
audited each year.
''(C) Mandatory exclusion.--A recipient of grant
funds under this part that is found to have an
unresolved audit finding shall not be eligible to
receive grant funds under this part during the first 2
fiscal years beginning after the end of the 12-month
period described in subparagraph (A).
''(D) Priority.--In awarding grants under this
part, the Attorney General shall give priority to
eligible applicants that did not have an unresolved
audit finding during the 3 fiscal years before
submitting an application for a grant under this part.
''(E) Reimbursement.--If an entity is awarded grant
funds under this part during the 2-fiscal-year period
during which the entity is barred from receiving grants
under subparagraph (C), the Attorney General shall--
''(i) deposit an amount equal to the amount
of the grant funds that were improperly awarded
to the grantee into the General Fund of the
Treasury; and
''(ii) seek to recoup the costs of the
repayment to the fund from the grant recipient
that was erroneously awarded grant funds.
''(2) Annual certification.--Beginning in the first fiscal
year beginning after the date of enactment of this section, the
Attorney General shall submit to the applicable committees an
annual certification--
''(A) indicating whether--
''(i) all audits issued by the Inspector
General of the Department of Justice under
paragraph (1) have been completed and reviewed
by the appropriate Assistant Attorney General
or Director;
''(ii) all mandatory exclusions required
under paragraph (1)(C) have been issued; and
''(iii) all reimbursements required under
paragraph (1)(E) have been made; and
''(B) that includes a list of any grant recipients
excluded under paragraph (1) from the previous year.
''(c) Preventing Duplicative Grants.--
''(1) In general.--Before the Attorney General awards a
grant to an applicant under this part, the Attorney General
shall compare potential grant awards with other grants awarded
under this part by the Attorney General to determine if
duplicate grant awards are awarded for the same purpose.
''(2) Report.--If the Attorney General awards duplicate
grants under this part to the same applicant for the same
purpose, the Attorney General shall submit to the applicable
committees a report that includes--
''(A) a list of all duplicate grants awarded under
this part, including the total dollar amount of any
duplicate grants awarded; and
''(B) the reason the Attorney General awarded the
duplicate grants.''.

SEC. 3. SENSE OF CONGRESS.

It is the sense of the Congress that the use of best practices is
encouraged for all activities for which grants under part R of title I
of the Omnibus Crime Control and Safe Streets Act of 1968 may be used.

SEC. 4. USE OF AMOUNTS MADE AVAILABLE FOR DEPARTMENT OF JUSTICE,
GENERAL ADMINISTRATION TO CARRY OUT JUVENILE
ACCOUNTABILITY BLOCK GRANT PROGRAM.

In each of fiscal years 2018 through 2022, the Attorney General
shall use up to $25,000,000 of the amounts made available for
Department of Justice, General Administration, to carry out part R of
title I of the Omnibus Crime Control and Safe Streets Act of 1968 (42
U.S.C. 3796ee et seq.).
Amend the title so as to read: ''A bill to amend the
Omnibus Crime Control and Safe Streets Act of 1968 to
reauthorize the Juvenile Accountability Block Grant program,
and for other purposes.''.
answer:
Tiffany Joslyn Juvenile Accountability Block Grant Program Reauthorization Act of 2016 (Sec. 2) This bill amends the Omnibus Crime Control and Safe Streets Act of 1968 to revise and reauthorize through FY2022 the Juvenile Accountability Block Grant (JABG) Program. It subjects JABG grants to accountability measures. The Department of Justice's (DOJ's) Office of Inspector General must conduct annual audits of selected grant recipients. DOJ must submit an annual certification to Congress and identify and report on duplicative grant awards. (Sec. 3) The bill expresses the sense of Congress that the use of best practices is encouraged for activities carried out with JABG funds. (Sec. 4) DOJ must use amounts made available for general administration to carry out the JABG Program.

question:
SECTION 1. SHORT TITLE.

This Act may be cited as the ''Medicare Market Acquisition Drug
Price Act of 2002''.

SEC. 2. REFORM OF PAYMENT FOR DRUGS AND BIOLOGICALS UNDER THE MEDICARE
PROGRAM.

(a) Payment Reform.--
(1) In general.--Section 1842(o) of the Social Security Act
(42 U.S.C. 1395u(o)) is amended to read as follows:
''(o) Payment for Drugs and Biologicals.--
''(1) General rule.--If a physician's, supplier's, or any
other person's bill or request for payment for services
includes a charge for a drug or biological for which payment
may be made under this part and the drug or biological is not
paid on a cost or prospective payment basis as otherwise
provided in this part, the amount payable for the drug or
biological shall be based on the following:
''(A) Multi-source (generic) drugs.--In the case of
a drug or biological that meets the requirements for a
multi-source drug under subclauses (I) and (II) of
section 1927(k)(7)(A)(i), 105 percent of the volume-
weighted median average acquisition price for any drug
or biological covered under the same medicare HCPCS
code.
''(B) Single source (brand) drugs and
biologicals.--In the case of a drug or biological that
meets the requirements for a single source drug under
section 1927(k)(7)(A)(iv), 105 percent of the average
acquisition price for the drug or biological.
''(C) Access exception.--The Secretary may modify
the rate otherwise applicable in order to assure access
to necessary drugs and biologicals in the case of sole
community providers in rural and other areas where the
providers are not reasonably able to obtain the drugs
and biologicals at the payment rates otherwise
applicable. Such modification shall not result in a
change of more than 15 percent of the rate otherwise
applicable.
''(D) Data-related exception.--If the Secretary
determines that there is insufficient data available
with respect to compute an average acquisition price
for a drug or biological for a quarter or that, because
of a significant change in price from quarter-to-
quarter, the available data on the average acquisition
price does not accurately reflect the actual, current
acquisition cost for the drug or biological, the
Secretary may substitute for the quarters involved an
appropriate payment for the drug or biological for such
average acquisition price.
''(E) Application of ndc codes.--If the Secretary
determines that it is appropriate to provide for
payment under this subsection using national drug code
(NDC) instead of HCPCS codes, in applying subparagraph
(A) the reference to the same HCPCS code shall be
deemed a reference to the appropriate national drug
codes for those drugs or biologicals that are
therapeutically and pharmaceutically equivalent and
bioequivalent (as defined for purposes of section
1927(k)(7)(A)).
''(2) Definition of average acquisition price.--
''(A) In general.--For purposes of this subsection,
the term 'average acquisition price' means, with
respect to a drug or biological and with respect to
each dosage form and strength of the drug or biological
product (without regard to any special packaging,
labeling, or identifiers on the dosage form or product
or package), the average of all final sales prices
charged by the manufacturer of the drug or biological
product in the United States, excluding sales exempt
from inclusion in the calculation of best price under section
1927(c)(1)(C) (other than under clause (ii)(III) of such section) and
excluding sales subject to a rebate under section 1927, as reported
under paragraph (3).
''(B) Net price.--Such average acquisition price
shall be calculated net of all of the following (as
estimated by the Secretary):
''(i) Volume discounts.
''(ii) Prompt pay discounts and cash
discounts.
''(iii) Charge-backs.
''(iv) Short-dated product discounts (for
spoilage and other factors).
''(v) Free goods and services.
''(vi) Rebates.
''(vii) All other price concessions
provided by the drug manufacturer.
The Secretary may make subsequent adjustments in such
average acquisition price to take into account updated
information and differences between the price
previously estimated and the actual average acquisition
price.
''(C) Weighting.--The average of all final sales
prices described in subparagraph (A) shall be
determined by dividing--
''(i) the sum of all final prices charged
by the manufacturer (net of the adjustments
made under subparagraph (B)) for sales in the
period involved that are included in
subparagraph (A) for the drug or biological, by
''(ii) the total number of units of such
sales in the period.
''(D) Distribution of reports.--The Secretary shall
promptly distribute applicable payment rates under this
subsection to carriers and fiscal intermediaries and
other contractors that make payment for drugs and
biologicals under this section in order to apply a
uniform reimbursement rate under this section.
''(3) Price reporting requirement.--
''(A) In general.--As a condition for payment for
any drug or biological of a manufacturer under this
subsection, the manufacturer of the drug or biological
shall--
''(i) report, on a quarterly basis, to the
Secretary (or the Secretary's designee) the
manufacturer's average acquisition price and
the information required under subparagraph (C)
for all drugs and biologicals of the
manufacturer by national drug code (NDC);
''(ii) maintain such records (in written or
electronic form) regarding such sales and
prices for all such drugs and biologicals as
may be necessary to audit the information so
reported or required to be reported; and
''(iii) provide the Secretary with access
to such records in order to permit the
Secretary to audit information so reported or
required to be reported.
''(B) Penalties.--The provisions of section
1927(b)(3)(C) shall apply with respect to the reporting
of information under subparagraph (A) in the same
manner as it applies to the reporting of information
under section 1927(b)(3)(A), except that the reference
in clause (i) of such section to $10,000 is deemed a
reference to $100,000 and any reference to a suspension
of an agreement is deemed a reference to a suspension
of payment for the drug or biological involved under
this part. The Secretary shall promptly refer to the
Inspector General of the Department of Health and Human
Services and, if appropriate, to appropriate officials
in the Department of Justice cases in which the
Secretary becomes aware of a false price representation
made in the information submitted under this paragraph.
''(C) Form of reporting.--Information required to
be reported under subparagraph (A)(i) shall be reported
in a form and manner specified by the Secretary. The
information required to be reported shall include the
identification of the generic name of the drug or
biological and its brand name (if any), the national
drug code (NDC) and the HCPCS code assigned to the drug
or biological, the dosage form, strength, volume, and
package size involved. The information for a quarter
shall be submitted not later than 30 days after the end
of the quarter. The information shall be accompanied by
a written and signed certification by an officer of the
manufacturer attesting to the accuracy of the
information reported. Such information shall include
updated information on the net price realized (taking
into account rebates and other amounts affecting net price), regardless
of the period for which such a rebate or other adjustment in net price
might have been earned.
''(D) Auditing.--The Secretary shall audit on a
periodic basis information reported or required to be
reported under this paragraph. The Secretary may
conduct such independent price gathering activities,
such as surveys and review of published catalog
information or other transactional information, as may
be appropriate to verify the accuracy of the
information reported.
''(4) Dispensing fee.--If payment for a drug or biological
is made to a licensed pharmacy approved to dispense drugs or
biologicals under this part, the Secretary shall pay a
dispensing fee (less the applicable deductible and coinsurance
amounts) to the pharmacy. Such a dispensing fee shall be
subject to adjustment from year to year based upon changes in
the consumer price index over time and may be adjusted as the
Secretary determines to be appropriate to reflect differences
in the costs of dispensing different drugs and biologicals.
''(5) Payment required on an assignment-related basis.--
''(A) In general.--Payment for a charge for any
drug or biological for which payment may be made under
this part may be made only on an assignment-related
basis.
''(B) Application of enforcement provisions.--The
provisions of subsection (b)(18)(B) shall apply to
charges for such drugs or biologicals in the same
manner as they apply to services furnished by a
practitioner described in subsection (b)(18)(C).''.
(2) Effective date.--Subject to subsection (c)(2), the
amendment made by paragraph (1) shall apply to drugs and
biologicals furnished on or after January 1, 2003.
(b) Revision in Practice Expense Payments.--
(1) Adjustment in oncologist medical supply expenses.--In
computing the practice expense component of the physician fee
schedule under section 1848 of the Social Security Act (42
U.S.C. 1395w-4) with respect to payment for services of
oncologists, the Secretary of Health and Human Services shall
make adjustments to oncologists' reported medical supply
expenses in order to ensure that such expenses better reflect
the actual supply costs of providing such services.
(2) Allocation of indirect expenses.--In establishing such
fee schedule, the Secretary shall change the allocation of
indirect expenses in a manner so that all services, including
services without direct physician involvement, are allocated
the appropriate share of indirect expenses.
(3) Services without direct physician involvement.--In
establishing such fee schedule, the Secretary shall calculate
payments, for those services without direct physician
involvement under the basic method, using information on the
resources required for each services and, if deemed necessary,
shall validate the underlying resource-based estimates of
direct practice expenses required to provide each service.
(4) Budget neutral adjustment.--The changes in payment made
by this subsection shall not be treated as a change in law or
regulation described in section 1848(f)(2)(D) of the Social
Security Act (42 U.S.C. 1395w-4(f)(2)(D)).
(5) Effective date.--The provisions of this subsection
apply to payments for services furnished on or after January 1,
2003.
(c) Study of Payments for Blood Clotting Factors and Other
Biologicals.--
(1) In general.--The Secretary of Health and Human Services
shall provide for a study of the appropriateness of the
medicare payment methodology for blood clotting factors and
other biologicals under part B of title XVIII of the Social
Security Act. Not later than 9 months after the date of the
enactment of this Act, the Secretary shall submit to Congress a
report on such study and shall include in such report
recommendations regarding whether to apply the payment
methodology provided under the amendment made by subsection
(a)(1) and alternative recommendations for appropriate
dispensing fees.
(2) Delay in effective date.--The amendment made by
subsection (a)(1) shall not apply to blood clotting factors
furnished before the first day of the first calendar year that
begins at least 6 months after the date the report under
paragraph (1) has been submitted to the Congress.
answer:
Medicare Market Acquisition Drug Price Act of 2002 - Amends title XVIII (Medicare) of the Social Security Act (SSA) to revise payment for drugs and biologicals under Medicare.Directs the Secretary of Health and Human Services, in computing the practice expense component of the Medicare physician fee schedule with respect to payment for services of oncologists, to make adjustments to an oncologist's reported medical supply expenses in order to ensure that they better reflect the actual supply costs of providing such services.